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Methods: The 21-month longitudinal study included 159 subjects
prospectively selected as representative for the general population. From
these, only those over 30 years at follow-up were included to ensure a
homogeneous population. In total, 123 completed the study, age 58±14,
BMI 26±4, 47% female, and 54% with OA (Kellgren and Lawrence,
KL 1). Radiographs were acquired in a load-bearing semi-ﬂexed po-
sition using the SynaFlex (Synarc) and joint space width (JSW) was
measured. MRI scans with near-isotropic voxels were acquired from a
Turbo 3D T1 sequence from a 0.18T Esaote scanner (40º FA, TR 50ms,
TE 16ms, scan time 10 minutes, resolution 0.7mm×0.7mm×0.8mm)
and markers for volume, thickness, smoothness, homogeneity, and cur-
vature were quantiﬁed in a fully automatic computer-based framework.
Bone resorption was measured by the biochemical marker serum CTX-I
(C-terminal telopeptide of collagen type I) and cartilage degradation by
urine CTX-II (collagen type II, sample acquired as second morning void).
Pain was quantiﬁed by a visual assessment scale (VAS). Radiograph and
MRI markers were averaged for left and right medial compartments and
MRI markers were the sum of tibial and femoral compartments. Cross-
sectional biomarker scores and longitudinal changes over 21 months
were tested for association with pain and evaluated by correlation (r),
t-test of whether scores are higher in the group with pain (p), and odds
ratio for high scores relating to pain (OR).
Results: For all markers, the results are listed in Table 1. Cross-
sectionally at follow-up, BMI and CTX-II were associated with pain,
whereas age, JSW and homogeneity were borderline associated. Lon-
gitudinally, the changes from baseline to follow-up were borderline asso-
ciated with pain at follow-up for homogeneity and CTX-II. For CTX-II and
homogeneity this persisted after linear correction for gender and age (GA
cor).
Biomarker associations with pain, cross-sectional (C) and longitudinal (L)
r (C) p (C) OR (C) r (L) p (L) OR (L)
Age 0.21 0.053 3.8 *
Gender 0.02 0.445 1.4
BMI 0.26* 0.021* 3.3* −0.10 0.288 1.9
JSW −0.19 0.062 3.1* −0.09 0.737 1.2
CTX-I −0.16 0.028* 2.9 0.09 0.129 2.3
CTX-II 0.29** 0.001** 7.1** 0.05 0.077 3.2*
Volume −0.13 0.681 1.5 −0.16 0.063 2.3
Thickness −0.19 0.425 1.3 −0.14 0.866 0.9
Smoothness −0.13 0.936 0.9 −0.05 1.000 1.1
Homogeneity 0.22* 0.090 2.3 0.20 0.043* 3.3*
Curvature −0.02 0.549 1.4 0.06 0.973 0.7
CTX-II (GA cor) 0.28* 0.003** 7.1* 0.05 0.077 3.2*
Hom. (GA cor) 0.23* 0.099 2.3 0.20 0.043* 3.3*
Conclusions: The results in this study indicated that pain was associated
with the biochemical marker for cartilage breakdown (CTX-II) rather
than bone turnover (CTX-I). Furthermore, pain was associated with
the cartilage marker related to internal structure (homogeneity) rather
than denudation (volume or thickness). Combined, these results may
indicate that early stage cartilage breakdown should not be ignored
by treatment development targeting pain prevention. Measurement of
pain in longitudinal clinical studies is challenging due to poor precision
and confounding effects. Therefore, the cross-sectional and longitudinal
associations between pain and cartilage homogeneity (that has inter-scan
RMS CV 1.0%) merits further research to reveal whether homogeneity
may be a suitable surrogate marker for pain.
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Purpose: Altered subchondral bone remodeling and structure have been
suggested to play a role in the development of osteoarthritis (OA). Recent
animal studies have shown progressive articular cartilage degradation
in a mouse model of osteogenesis imperfecta (OI), a disease caused
by mutations in type I collagen (Col I) genes which are associated with
abnormal bone matrix. The aim of this study was to investigate whether
adult patients with OI used as a human model of bone Col-I defect, are
characterized by increased cartilage type II collagen (Col-II) degradation.
Methods: Sixty four patients with mild OI (25 women, 39 men; mean
age (SD): 36.2 (11.6) year) participating in a randomized study and 64
sex and age matched healthy controls were included. In patients with OI
and controls, we assessed the following bone Col-I and cartilage Col-II
parameters using speciﬁc biochemical markers: (1) Col I synthesis by
serum N-propeptide (PINP), (2) Col-I degradation by urinary fragments
of the helical domain of Col-I (Helix-I), (3) Col-I maturation by the
urinary ratio of native (a CTX-I) to isomerized (b CTX-I) aspartic acid
of Col-I C-telopeptide (a/b CTX-I). Isomerization is a post-translational
modiﬁcation of Col I reﬂecting the degree of bone matrix maturation
which has shown to be associated with altered structure, a high urinary
a/b CTX-I ratio being indicative of lower bone matrix maturation and
(4) Col-II degradation by urinary C-terminal telopeptide fragments (CTX-
II).
Results: As shown on the table, compared to healthy controls, adults
with OI had signiﬁcantly decreased bone Col-I synthesis (lower PINP),
increased bone Col-I degradation (higher Helix-I), decreased bone Col-I
maturation (higher a/b CTX-I ratio) and a marked increase in cartilage Col-
II degradation (high CTX-II). In patients with OI, urinary CTX-II correlated
with Helix-I, (r = 0.48, <0.0001) suggesting an association between bone
Col I and cartilage Col II degradation.
Conclusions: Cartilage type II collagen degradation is increased in a
human model of bone type I collagen defect. These data are in agreement
with animal studies suggesting that altered subchondral bone remodeling







OI (n = 64) 32.3±19.8* 67.7±40.0* 2.04±0.72* 460±576*
Controls (n = 64) 41.8±13.5 42.8±19.4 1.37±0.43 143±62
*p< 0.001 vs controls; results are means±SD.
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Purpose: The molecular changes that occur in the early stages of
osteoarthritis (OA) are poorly understood. The aim of this study was to
use a targeted proteomic approach aimed at identiﬁcation of secreted
biomarkers from equine cartilage explants stimulated with recombinant
equine interleukin-1 beta (Il-1b).
Methods: Equine articular cartilage was obtained from weight bearing
regions of metatarsophalangeal joints of horses euthanized for purposes
other than for research. Full depth cartilage discs were excised with a
biopsy punch and washed extensively in PBS and serum free DMEM.
Explants were either incubated alone (control), or with Il-1b (10 ng×ml−1)
at 37ºC for 5 days. Supernatants were then removed and frozen before
trypsin digestion overnight at 37ºC. The reaction was stopped with formic
acid and the samples were stored at −80ºC until proteomic analysis by
ESI (Electrospray Ionisation) mass spectrometry. Peptides were sepa-
rated on a C18 pepmap column using a Dionex U3000 chromatography
platform and detected in a Bruker HCT PTM discovery ion trap instrument.
The four most abundant peptides in each MS scan were selected for
fragmentation. Using MASCOT search engine the fragment patterns
for each were compared to the mammalian entries in the SwissProt
database. The modiﬁcations incorporated into the search were: ﬁxed
carbamidomethyl cysteine, variable oxidation of methionine and variable
deamidation of asparagine and glutamine residues.
Results: Comparative proteomic analysis of the supernatants identiﬁed
a number of relevant proteins. Tryptic peptides originating from aggrecan
core protein, cartilage oligomeric matrix protein (COMP), ﬁbronectin,
ﬁbromodulin, thrombospondin-1 (TSP-1) and matrix metalloproteinases
MMP-1 and MMP-3 were detected. Several novel and unexpected se-
creted proteins were also identiﬁed including clusterin, cartilage interme-
diate layer protein-1 (CILP-1) and chondroadherin (CHAD) precursor.
Conclusions: This study has highlighted the presence of several novel
biomarkers in the supernatants of cartilage explants stimulated with Il-1b.
Many of the identiﬁed proteins have putative matrix functions including
participation in cell-matrix and matrix-matrix interactions (i.e. ﬁbronectin,
TSP-1, COMP, CHAD), matrix turnover (MMP-1, MMP-3) and extracellular
